StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research report sent to investors on Friday morning. The firm issued a sell rating on the medical research company’s stock.
Organovo Trading Up 1.2 %
Shares of ONVO opened at $1.00 on Friday. The stock has a 50 day moving average of $1.04 and a 200-day moving average of $1.12. Organovo has a 52 week low of $0.89 and a 52 week high of $2.05.
Organovo (NASDAQ:ONVO – Get Free Report) last issued its earnings results on Thursday, February 8th. The medical research company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.08 million. Analysts expect that Organovo will post -1.74 earnings per share for the current fiscal year.
Organovo Company Profile
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Read More
- Five stocks we like better than Organovo
- The 3 Best Fintech Stocks to Buy Now
- MarketBeat Week in Review – 4/22 – 4/26
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.
